CSTL Castle Biosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CSTL

Price (delayed)

$21.58

Market cap

$654.52M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.42

Enterprise value

$627.48M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 32

Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently ...

Highlights
CSTL's EPS has dropped by 180% year-on-year but it is up by 49% since the previous quarter
The net income has dropped by 153% year-on-year but it rose by 47% since the previous quarter
The debt has increased by 42% YoY
The gross profit has contracted by 7% YoY and by 3.1% from the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.castlebiosciences.com
Peers: OPK ORGO

Key stats

What are the main financial stats of CSTL

CSTL stock price

How has the Castle Biosciences stock price performed over time
Intraday
5.84%
1 week
-2.4%
1 month
-15.44%
1 year
26.79%
YTD
-44.52%
QTD
-12.1%

Financial performance

How have Castle Biosciences's revenue and profit performed over time
Revenue
$339.92M
Gross profit
$264.74M
Operating income
-$33.29M
Net income
-$12.83M
Gross margin
77.9%
Net margin
-3.8%
The net margin has shrunk by 153% YoY but it has increased by 46% QoQ
The net income has dropped by 153% year-on-year but it rose by 47% since the previous quarter
The operating margin has dropped by 145% year-on-year but it has grown by 21% since the previous quarter
The operating income has plunged by 141% YoY but it has grown by 22% from the previous quarter

Price vs fundamentals

How does CSTL's price correlate with its fundamentals

Growth

What is Castle Biosciences's growth rate over time

Valuation

What is Castle Biosciences stock price valuation
CSTL P/E details
P/E
N/A
P/B
1.39
P/S
1.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.85
CSTL's EPS has dropped by 180% year-on-year but it is up by 49% since the previous quarter
CSTL's price to book (P/B) is 31% lower than its 5-year quarterly average of 1.9 and 23% lower than its last 4 quarters average of 1.7
The equity is up by 4.8% year-on-year but it has declined by 2% since the previous quarter
The P/S is 68% below the 5-year quarterly average of 5.6 and 22% below the last 4 quarters average of 2.3
CSTL's revenue is down by 2.1% YoY

Efficiency

How efficient is Castle Biosciences business performance
The ROE has shrunk by 133% YoY but it rose by 47% QoQ
Castle Biosciences's return on assets has shrunk by 130% YoY but it has increased by 48% QoQ
Castle Biosciences's return on invested capital has increased by 43% QoQ
CSTL's return on sales is up by 40% since the previous quarter

Dividends

What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CSTL.

Financial health

How did Castle Biosciences financials performed over time
The total liabilities has grown by 41% year-on-year but it has declined by 20% since the previous quarter
Castle Biosciences's quick ratio has decreased by 30% YoY but it has increased by 25% QoQ
The debt is 92% lower than the equity
The debt has increased by 42% YoY
CSTL's debt to equity is up by 33% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.